Only open-market buys / sells (codes P/S) are a conviction signal; grants, option exercises, tax-withholding, and gifts are compensation mechanics, shown but greyed. The trailing 12-month tallies run to today but the store covers filings through 2026-06-30 only (SEC bulk data sets publish quarterly), so recent activity may be absent.
| Date | Insider | Role | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-15 | Friedberg Ezra M | Director | −Sell | 59 | $27.94 | $1,648 |
| 2026-06-15 | Friedberg Ezra M | Director | −Sell | 224 | $27.12 | $6,075 |
| 2026-06-11 | Davis Todd C | Director | +Buy | 35,445 | $27.80 | $985,371 |
| 2026-06-11 | Davis Todd C | Director | +Buy | 503 | $28.73 | $14,451 |
| 2026-05-22 | Francis Knuettel II | Officer | −Disp→issuer | 13,947 | — | — |
| 2026-05-22 | Francis Knuettel II | Officer | −Sell | 1,500 | $26.84 | $40,260 |
| 2026-05-14 | Friedberg Ezra M | Director | −Tax w/h | 144 | $27.01 | $3,889 |
| 2026-04-02 | Greenleaf Peter | Director | −Sell | 377 | $21.36 | $8,053 |
| 2026-04-02 | Greenleaf Peter | Director | −Sell | 420 | $20.52 | $8,618 |
| 2026-04-02 | Pauls Matthew | Director | −Sell | 415 | $20.52 | $8,516 |
| 2026-04-02 | Pauls Matthew | Director | −Sell | 371 | $21.36 | $7,925 |
| 2026-04-02 | Friedberg Ezra M | Director | −Sell | 265 | $21.36 | $5,660 |
| 2026-04-02 | Friedberg Ezra M | Director | −Sell | 293 | $20.51 | $6,009 |
| 2026-04-02 | Malamut Richard | Director | −Sell | 280 | $21.36 | $5,981 |
| 2026-04-02 | Malamut Richard | Director | −Sell | 310 | $20.51 | $6,358 |
| 2025-12-23 | Einhorn Andrew J. | Director | +Grant | 12,000 | — | — |
| 2025-12-10 | Pauls Matthew | Director | −Gift | 9,542 | — | — |
| 2025-11-25 | Friedberg Ezra M | Director | −Sell | 2,000 | $28.14 | $56,280 |
| 2025-11-25 | Friedberg Ezra M | Director | −Sell | 1 | $28.50 | $29 |
| 2025-11-25 | Friedberg Ezra M | Director | −Sell | 2,000 | $28.01 | $56,020 |
| 2025-11-25 | Friedberg Ezra M | Director | −Sell | 5,999 | $28.00 | $167,972 |
| 2025-11-13 | Malamut Richard | Director | +Grant | 2,454 | — | — |
| 2025-10-02 | Pauls Matthew | Director | +Exercise | 2,123 | — | — |
| 2025-07-02 | Pauls Matthew | Director | +Exercise | 8,493 | — | — |
| 2025-07-02 | Francis Knuettel II | Officer | +Grant | 33,472 | — | — |
| 2025-07-02 | Baxter Richard B | Director | +Grant | 19,108 | — | — |
| 2025-07-02 | Rangarao Sai | Officer | +Grant | 30,518 | — | — |
| 2025-07-02 | Pauls Matthew | Director | +Grant | 25,478 | — | — |
| 2025-07-02 | Greenleaf Peter | Director | +Grant | 25,478 | — | — |
| 2025-07-02 | Plesha Scott M. | Director,Officer | +Grant | 83,678 | — | — |
| 2025-07-02 | Malamut Richard | Director | +Grant | 19,108 | — | — |
| 2025-07-02 | Davis Todd C | Director | +Grant | 19,108 | — | — |
| 2025-07-02 | Friedberg Ezra M | Director | +Grant | 19,108 | — | — |
| 2025-07-01 | LIGAND PHARMACEUTICALS INC | TenPercentOwner | +Conversion | 1,500,000 | $10.00 | $15M |
| 2025-07-01 | Davis Todd C | Director,TenPercentOwner | +Conversion | 1,500,000 | $10.00 | $15M |
| 2025-07-01 | Francis Knuettel II | Officer | +Conversion | 10,000 | $10.00 | $100,000 |
| 2025-07-01 | Friedberg Ezra M | Director | +Conversion | 40,000 | $10.00 | $400,000 |
| 2025-07-01 | Friedberg Ezra M | Director | +Conversion | 40,000 | $10.00 | $400,000 |
| 2024-11-13 | Davis Todd C | Director | +Grant | 4,961 | — | — |
| 2024-11-13 | Friedberg Ezra M | Director | +Grant | 2,454 | — | — |
| 2024-06-14 | Malamut Richard | Director | +Grant | 6,450 | — | — |
| 2024-06-14 | Davis Todd C | Director | +Grant | 12,900 | — | — |
| 2024-06-14 | Friedberg Ezra M | Director | +Grant | 6,450 | — | — |
Source: the SEC bulk insider (Form 3/4/5) data sets — non-derivative transactions in the issuer's common stock, most recent first, covering filings through 2026-06-30. Insiders file within 2 business days of a transaction, but the bulk sets publish quarterly, so this store lags live filings; option/derivative lines are excluded. Codes: P buy · S sell · A grant · M/X/C exercise · F tax · G gift.
Model-derived estimate for research. See the Disclaimer.
